Skip to main content
Top
Published in: Cancer Causes & Control 2/2008

01-03-2008 | Original Paper

Joint effect between regular use of non-steroidal anti-inflammatory drugs, variants in inflammatory genes and risk of lymphoma

Authors: Birgit Hoeft, Nikolaus Becker, Evelin Deeg, Lars Beckmann, Alexandra Nieters

Published in: Cancer Causes & Control | Issue 2/2008

Login to get access

Abstract

Objective

Limited evidence suggests the importance of inflammatory processes for the etiology of lymphomas. To further research in this area, we investigated the role of genetic variants in key inflammatory factors, non-steroidal anti-inflammatory drug [NSAID] use, and their joint effect in lymphomagenesis.

Methods

The study comprised 710 case–control pairs, matched for gender, age, and study region. We examined the association of regular NSAID use and polymorphisms in prostaglandin-endoperoxide synthase-2 (COX2), prostaglandin E synthase (PTGES), interleukin-1 alpha (IL1A), IL-1 beta (IL1B), and IL-1 receptor antagonist (IL1RA), and lymphoma risk by applying logistic regression to calculate odds ratios (OR) and 95% confidence intervals (95% CI).

Results

Regular NSAID use was associated with a slightly reduced risk of B-NHL (OR = 0.8, 95% CI = 0.6–1.1). For T-NHL, the COX2 rs2745557 A-allele conferred a 2.2-fold (95% CI = 1.1–4.5) and homozygosis for the IL1RN rs454078 T-allele was associated with a 4.5-fold (95% CI = 1.4–13.9) elevated risk, however, based on sparse data. IL1 haplotype 5 was associated with a statistically significant 43% increased risk for B-NHL among non-regular users of NSAIDs, but a 70% decreased risk for regular users (p-value for interaction < 0.001).

Conclusions

These results suggest the relevance of joint effects between NSAID use and IL1 haplotypes on the risk of B-NHL.
Literature
1.
go back to reference Jaffé ES, Harris NL, Stein H, Vardiman JWE (2001) World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon Jaffé ES, Harris NL, Stein H, Vardiman JWE (2001) World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon
2.
go back to reference Levi F, Lucchini F, Negri E, La Vecchia C (2002) Trends in mortality from non-Hodgkin’s lymphomas. Leuk Res 26:903–908PubMedCrossRef Levi F, Lucchini F, Negri E, La Vecchia C (2002) Trends in mortality from non-Hodgkin’s lymphomas. Leuk Res 26:903–908PubMedCrossRef
3.
go back to reference Cartwright R, Brincker H, Carli PM et al (1999) The rise in incidence of lymphomas in Europe 1985–1992. Eur J Cancer 35:627–633PubMedCrossRef Cartwright R, Brincker H, Carli PM et al (1999) The rise in incidence of lymphomas in Europe 1985–1992. Eur J Cancer 35:627–633PubMedCrossRef
4.
6.
go back to reference Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G (2006) Inflammation and cancer: how hot is the link? Biochem Pharmacol 72:1605–1621PubMedCrossRef Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G (2006) Inflammation and cancer: how hot is the link? Biochem Pharmacol 72:1605–1621PubMedCrossRef
8.
go back to reference Bosetti C, Gallus S, La VC (2006) Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control 17:871–888PubMedCrossRef Bosetti C, Gallus S, La VC (2006) Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control 17:871–888PubMedCrossRef
9.
go back to reference Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH (2003) A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 88:684–688PubMedCrossRef Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH (2003) A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 88:684–688PubMedCrossRef
10.
go back to reference Zhang Y, Holford TR, Leaderer B et al (2004) Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 15:419–428PubMedCrossRef Zhang Y, Holford TR, Leaderer B et al (2004) Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 15:419–428PubMedCrossRef
11.
go back to reference Flick ED, Chan KA, Bracci PM, Holly EA (2006) Use of nonsteroidal antiinflammatory drugs and non-Hodgkin lymphoma: a population-based case–control study. Am J Epidemiol 164:497–504PubMedCrossRef Flick ED, Chan KA, Bracci PM, Holly EA (2006) Use of nonsteroidal antiinflammatory drugs and non-Hodgkin lymphoma: a population-based case–control study. Am J Epidemiol 164:497–504PubMedCrossRef
12.
go back to reference Rosenberg L, Palmer JR, Zauber AG et al (1995) Relation of benzodiazepine use to the risk of selected cancers: breast, large bowel, malignant melanoma, lung, endometrium, ovary, non-Hodgkin’s lymphoma, testis, Hodgkin’s disease, thyroid, and liver. Am J Epidemiol 141:1153–1160PubMed Rosenberg L, Palmer JR, Zauber AG et al (1995) Relation of benzodiazepine use to the risk of selected cancers: breast, large bowel, malignant melanoma, lung, endometrium, ovary, non-Hodgkin’s lymphoma, testis, Hodgkin’s disease, thyroid, and liver. Am J Epidemiol 141:1153–1160PubMed
13.
go back to reference Bernstein L, Ross RK (1992) Prior medication use and health history as risk factors for non-Hodgkin’s lymphoma: preliminary results from a case–control study in Los Angeles County. Cancer Res 52:5510s–5515sPubMed Bernstein L, Ross RK (1992) Prior medication use and health history as risk factors for non-Hodgkin’s lymphoma: preliminary results from a case–control study in Los Angeles County. Cancer Res 52:5510s–5515sPubMed
14.
go back to reference Cerhan JR, Anderson KE, Janney CA, Vachon CM, Witzig TE, Habermann TM (2003) Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma. Int J Cancer 106:784–788PubMedCrossRef Cerhan JR, Anderson KE, Janney CA, Vachon CM, Witzig TE, Habermann TM (2003) Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma. Int J Cancer 106:784–788PubMedCrossRef
15.
go back to reference Kato I, Koenig KL, Shore RE et al (2002) Use of anti-inflammatory and non-narcotic analgesic drugs and risk of non-Hodgkin’s lymphoma (NHL) (United States). Cancer Causes Control 13:965–974PubMedCrossRef Kato I, Koenig KL, Shore RE et al (2002) Use of anti-inflammatory and non-narcotic analgesic drugs and risk of non-Hodgkin’s lymphoma (NHL) (United States). Cancer Causes Control 13:965–974PubMedCrossRef
16.
go back to reference Chang ET, Smedby KE, Hjalgrim H et al (2005) Medication use and risk of non-Hodgkin’s lymphoma. Am J Epidemiol 162:965–974PubMedCrossRef Chang ET, Smedby KE, Hjalgrim H et al (2005) Medication use and risk of non-Hodgkin’s lymphoma. Am J Epidemiol 162:965–974PubMedCrossRef
17.
go back to reference Beiderbeck AB, Holly EA, Sturkenboom MC, Coebergh JW, Stricker BH, Leufkens HG (2003) Prescription medications associated with a decreased risk of non-Hodgkin’s lymphoma. Am J Epidemiol 157:510–516PubMedCrossRef Beiderbeck AB, Holly EA, Sturkenboom MC, Coebergh JW, Stricker BH, Leufkens HG (2003) Prescription medications associated with a decreased risk of non-Hodgkin’s lymphoma. Am J Epidemiol 157:510–516PubMedCrossRef
18.
go back to reference Holly EA, Lele C, Bracci PM, McGrath MS (1999) Case–control study of non-Hodgkin’s lymphoma among women and heterosexual men in the San Francisco Bay Area, California. Am J Epidemiol 150:375–389PubMed Holly EA, Lele C, Bracci PM, McGrath MS (1999) Case–control study of non-Hodgkin’s lymphoma among women and heterosexual men in the San Francisco Bay Area, California. Am J Epidemiol 150:375–389PubMed
19.
go back to reference Holly EA, Bracci PM (2003) Population-based study of non-Hodgkin lymphoma, histology, and medical history among human immunodeficiency virus-negative participants in San Francisco. Am J Epidemiol 158:316–327PubMedCrossRef Holly EA, Bracci PM (2003) Population-based study of non-Hodgkin lymphoma, histology, and medical history among human immunodeficiency virus-negative participants in San Francisco. Am J Epidemiol 158:316–327PubMedCrossRef
20.
go back to reference Baker JA, Weiss JR, Czuczman MS, Menezes RJ, Ambrosone CB, Moysich KB (2005) Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphoma. Cancer Causes Control 16:301–308PubMedCrossRef Baker JA, Weiss JR, Czuczman MS, Menezes RJ, Ambrosone CB, Moysich KB (2005) Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphoma. Cancer Causes Control 16:301–308PubMedCrossRef
21.
go back to reference Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L (2006) Risk of non-Hodgkin lymphoma and use of non-steroidal anti-inflammatory drugs. Cancer Detect Prev 30:99–101PubMedCrossRef Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L (2006) Risk of non-Hodgkin lymphoma and use of non-steroidal anti-inflammatory drugs. Cancer Detect Prev 30:99–101PubMedCrossRef
22.
go back to reference Chang ET, Zheng T, Weir EG et al (2004) Aspirin and the risk of Hodgkin’s lymphoma in a population-based case–control study. J Natl Cancer Inst 96:305–315PubMedCrossRef Chang ET, Zheng T, Weir EG et al (2004) Aspirin and the risk of Hodgkin’s lymphoma in a population-based case–control study. J Natl Cancer Inst 96:305–315PubMedCrossRef
23.
go back to reference Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr (1993) Aspirin use and risk of fatal cancer. Cancer Res 53:1322–1327PubMed Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr (1993) Aspirin use and risk of fatal cancer. Cancer Res 53:1322–1327PubMed
24.
go back to reference Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E (2004) Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 24:3177–3184PubMed Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E (2004) Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 24:3177–3184PubMed
25.
go back to reference Roper RL, Phipps RP (1992) Prostaglandin E2 and cAMP inhibit B lymphocyte activation and simultaneously promote IgE and IgG1 synthesis. J Immunol 149:2984–2991PubMed Roper RL, Phipps RP (1992) Prostaglandin E2 and cAMP inhibit B lymphocyte activation and simultaneously promote IgE and IgG1 synthesis. J Immunol 149:2984–2991PubMed
26.
go back to reference Stein SH, Phipps RP (1992) Anti-class II antibodies potentiate IgG2a production by lipopolysaccharide-stimulated B lymphocytes treated with prostaglandin E2 and IFN-gamma. J Immunol 148:3943–3949PubMed Stein SH, Phipps RP (1992) Anti-class II antibodies potentiate IgG2a production by lipopolysaccharide-stimulated B lymphocytes treated with prostaglandin E2 and IFN-gamma. J Immunol 148:3943–3949PubMed
27.
go back to reference IARC (1997) Non-steroidal anti-inflammatory drugs. IARC, Lyon IARC (1997) Non-steroidal anti-inflammatory drugs. IARC, Lyon
28.
go back to reference Goodwin JS, Messner RP, Bankhurst AD, Peake GT, Saiki JH, Williams RC Jr (1977) Prostaglandin-producing suppressor cells in Hodgkin’s disease. N Engl J Med 297:963–968PubMedCrossRef Goodwin JS, Messner RP, Bankhurst AD, Peake GT, Saiki JH, Williams RC Jr (1977) Prostaglandin-producing suppressor cells in Hodgkin’s disease. N Engl J Med 297:963–968PubMedCrossRef
29.
go back to reference Cayeux SJ, Beverley PC, Schulz R, Dorken B (1993) Elevated plasma prostaglandin E2 levels found in 14 patients undergoing autologous bone marrow or stem cell transplantation. Bone Marrow Transplant 12:603–608PubMed Cayeux SJ, Beverley PC, Schulz R, Dorken B (1993) Elevated plasma prostaglandin E2 levels found in 14 patients undergoing autologous bone marrow or stem cell transplantation. Bone Marrow Transplant 12:603–608PubMed
30.
go back to reference Ladetto M, Vallet S, Trojan A et al (2005) Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood 105:4784–4791PubMedCrossRef Ladetto M, Vallet S, Trojan A et al (2005) Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood 105:4784–4791PubMedCrossRef
31.
go back to reference Hazar B, Ergin M, Seyrek E, Erdogan S, Tuncer I, Hakverdi S (2004) Cyclooxygenase-2 (Cox-2) expression in lymphomas. Leuk Lymphoma 45:1395–1399PubMedCrossRef Hazar B, Ergin M, Seyrek E, Erdogan S, Tuncer I, Hakverdi S (2004) Cyclooxygenase-2 (Cox-2) expression in lymphomas. Leuk Lymphoma 45:1395–1399PubMedCrossRef
32.
go back to reference Li HL, Sun BZ, Ma FC (2004) Expression of COX-2, iNOS, p53 and Ki-67 in gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol 10:1862–1866PubMed Li HL, Sun BZ, Ma FC (2004) Expression of COX-2, iNOS, p53 and Ki-67 in gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol 10:1862–1866PubMed
33.
go back to reference Paydas S, Ergin M, Erdogan S, Seydaoglu G (2007) Cyclooxygenase-2 expression in non-Hodgkin’s lymphomas. Leuk Lymphoma 48:389–395PubMedCrossRef Paydas S, Ergin M, Erdogan S, Seydaoglu G (2007) Cyclooxygenase-2 expression in non-Hodgkin’s lymphomas. Leuk Lymphoma 48:389–395PubMedCrossRef
35.
go back to reference Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 87:2095–2147PubMed Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 87:2095–2147PubMed
36.
go back to reference Dinarello CA, Thompson RC (1991) Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 12:404–410PubMedCrossRef Dinarello CA, Thompson RC (1991) Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 12:404–410PubMedCrossRef
37.
go back to reference Reznikov LL, Kim SH, Westcott JY et al (2000) IL-18 binding protein increases spontaneous and IL-1-induced prostaglandin production via inhibition of IFN-gamma. Proc Natl Acad Sci U S A 97:2174–2179PubMedCrossRef Reznikov LL, Kim SH, Westcott JY et al (2000) IL-18 binding protein increases spontaneous and IL-1-induced prostaglandin production via inhibition of IFN-gamma. Proc Natl Acad Sci U S A 97:2174–2179PubMedCrossRef
38.
go back to reference Cipollone F, Patrono C (2002) Cyclooxygenase-2 polymorphism: putting a brake on the inflammatory response to vascular injury? Arterioscler Thromb Vasc Biol 22:1516–1518PubMedCrossRef Cipollone F, Patrono C (2002) Cyclooxygenase-2 polymorphism: putting a brake on the inflammatory response to vascular injury? Arterioscler Thromb Vasc Biol 22:1516–1518PubMedCrossRef
39.
go back to reference Arend WP (2002) The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 13:323–340PubMedCrossRef Arend WP (2002) The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 13:323–340PubMedCrossRef
40.
go back to reference Cox DG, Pontes C, Guino E et al (2004) Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br J Cancer 91:339–343PubMed Cox DG, Pontes C, Guino E et al (2004) Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br J Cancer 91:339–343PubMed
41.
go back to reference Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A, Canzian F (2004) Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 25:229–235PubMedCrossRef Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A, Canzian F (2004) Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 25:229–235PubMedCrossRef
42.
go back to reference Gallicchio L, McSorley MA, Newschaffer CJ et al (2006) Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer 106:1443–1452PubMedCrossRef Gallicchio L, McSorley MA, Newschaffer CJ et al (2006) Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer 106:1443–1452PubMedCrossRef
43.
go back to reference Sakoda LC, Gao YT, Chen BE et al (2006) Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Carcinogenesis 27:1251–1256PubMedCrossRef Sakoda LC, Gao YT, Chen BE et al (2006) Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Carcinogenesis 27:1251–1256PubMedCrossRef
44.
go back to reference Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, Rothman N (2006) Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev 15:1126–1131PubMedCrossRef Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, Rothman N (2006) Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev 15:1126–1131PubMedCrossRef
45.
go back to reference Ulrich CM, Whitton J, Yu JH et al (2005) PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 14:616–619PubMedCrossRef Ulrich CM, Whitton J, Yu JH et al (2005) PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 14:616–619PubMedCrossRef
46.
go back to reference Siezen CL, van Leeuwen AI, Kram NR, Luken ME, van Kranen HJ, Kampman E (2005) Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption. Carcinogenesis 26:449–457PubMedCrossRef Siezen CL, van Leeuwen AI, Kram NR, Luken ME, van Kranen HJ, Kampman E (2005) Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption. Carcinogenesis 26:449–457PubMedCrossRef
47.
go back to reference Koh WP, Yuan JM, van den Berg D, Lee HP, Yu MC (2004) Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study. Br J Cancer 90:1760–1764PubMed Koh WP, Yuan JM, van den Berg D, Lee HP, Yu MC (2004) Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study. Br J Cancer 90:1760–1764PubMed
48.
go back to reference Hedelin M, Chang ET, Wiklund F et al (2007) Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. Int J Cancer 120:398–405PubMedCrossRef Hedelin M, Chang ET, Wiklund F et al (2007) Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. Int J Cancer 120:398–405PubMedCrossRef
49.
go back to reference Lightfoot T, Skibola CF, Adamson P et al (2006) Polymorphisms in the oxidative stress genes, superoxide dismutase, glutathione peroxidase and catalase and risk of non-Hodgin lymphoma. Haematologica 91(9):1222–1227PubMed Lightfoot T, Skibola CF, Adamson P et al (2006) Polymorphisms in the oxidative stress genes, superoxide dismutase, glutathione peroxidase and catalase and risk of non-Hodgin lymphoma. Haematologica 91(9):1222–1227PubMed
50.
go back to reference Becker N, Deeg E, Nieters A (2004) Population-based study of lymphoma in Germany: rationale, study design and first results. Leuk Res 28:713–724PubMedCrossRef Becker N, Deeg E, Nieters A (2004) Population-based study of lymphoma in Germany: rationale, study design and first results. Leuk Res 28:713–724PubMedCrossRef
51.
go back to reference Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70:425–434PubMedCrossRef Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70:425–434PubMedCrossRef
52.
go back to reference Lake SL, Lyon H, Tantisira K et al (2003) Estimation and tests of haplotype–environment interaction when linkage phase is ambiguous. Hum Hered 55:56–65PubMedCrossRef Lake SL, Lyon H, Tantisira K et al (2003) Estimation and tests of haplotype–environment interaction when linkage phase is ambiguous. Hum Hered 55:56–65PubMedCrossRef
53.
go back to reference Rothman N, Skibola CF, Wang SS et al (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 7:27–38PubMedCrossRef Rothman N, Skibola CF, Wang SS et al (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 7:27–38PubMedCrossRef
54.
go back to reference Endres S, Cannon JG, Ghorbani R et al (1989) In vitro production of IL 1 beta, IL 1 alpha, TNF and IL2 in healthy subjects: distribution, effect of cyclooxygenase inhibition and evidence of independent gene regulation. Eur J Immunol 19:2327–2333PubMedCrossRef Endres S, Cannon JG, Ghorbani R et al (1989) In vitro production of IL 1 beta, IL 1 alpha, TNF and IL2 in healthy subjects: distribution, effect of cyclooxygenase inhibition and evidence of independent gene regulation. Eur J Immunol 19:2327–2333PubMedCrossRef
55.
go back to reference Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252–266PubMed Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252–266PubMed
56.
go back to reference Ferroni P, Martini F, Cardarello CM, Gazzaniga PP, Davi G, Basili S (2003) Enhanced interleukin-1beta in hypercholesterolemia: effects of simvastatin and low-dose aspirin. Circulation 108:1673–1675PubMedCrossRef Ferroni P, Martini F, Cardarello CM, Gazzaniga PP, Davi G, Basili S (2003) Enhanced interleukin-1beta in hypercholesterolemia: effects of simvastatin and low-dose aspirin. Circulation 108:1673–1675PubMedCrossRef
57.
go back to reference Daun JM, Ball RW, Burger HR, Cannon JG (1999) Aspirin-induced increases in soluble IL-1 receptor type II concentrations in vitro and in vivo. J Leukoc Biol 65:863–866PubMed Daun JM, Ball RW, Burger HR, Cannon JG (1999) Aspirin-induced increases in soluble IL-1 receptor type II concentrations in vitro and in vivo. J Leukoc Biol 65:863–866PubMed
58.
go back to reference Tountas NA, Casini-Raggi V, Yang H et al (1999) Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. Gastroenterology 117:806–813PubMedCrossRef Tountas NA, Casini-Raggi V, Yang H et al (1999) Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. Gastroenterology 117:806–813PubMedCrossRef
59.
go back to reference Tolusso B, Pietrapertosa D, Morelli A et al (2006) IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. Pharmacogenomics 7:683–695PubMedCrossRef Tolusso B, Pietrapertosa D, Morelli A et al (2006) IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. Pharmacogenomics 7:683–695PubMedCrossRef
60.
go back to reference Santtila S, Savinainen K, Hurme M (1998) Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand J Immunol 47:195–198PubMedCrossRef Santtila S, Savinainen K, Hurme M (1998) Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand J Immunol 47:195–198PubMedCrossRef
61.
go back to reference Hurme M, Santtila S (1998) IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol 28:2598–2602PubMedCrossRef Hurme M, Santtila S (1998) IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol 28:2598–2602PubMedCrossRef
62.
go back to reference Vamvakopoulos J, Green C, Metcalfe S (2002) Genetic control of IL-1beta bioactivity through differential regulation of the IL-1 receptor antagonist. Eur J Immunol 32:2988–2996PubMedCrossRef Vamvakopoulos J, Green C, Metcalfe S (2002) Genetic control of IL-1beta bioactivity through differential regulation of the IL-1 receptor antagonist. Eur J Immunol 32:2988–2996PubMedCrossRef
63.
64.
go back to reference Philip M, Rowley DA, Schreiber H (2004) Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 14:433–439PubMedCrossRef Philip M, Rowley DA, Schreiber H (2004) Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 14:433–439PubMedCrossRef
65.
go back to reference Skibola C, Curry JD, Nieters A (2007) Genetic susceptibility to lymphoma. Haematologica 92(7):960–969PubMedCrossRef Skibola C, Curry JD, Nieters A (2007) Genetic susceptibility to lymphoma. Haematologica 92(7):960–969PubMedCrossRef
66.
go back to reference Zhu H, Liu C (2003) Interleukin-1 inhibits hepatitis C virus subgenomic RNA replication by activation of extracellular regulated kinase pathway. J Virol 77:5493–5498PubMedCrossRef Zhu H, Liu C (2003) Interleukin-1 inhibits hepatitis C virus subgenomic RNA replication by activation of extracellular regulated kinase pathway. J Virol 77:5493–5498PubMedCrossRef
67.
go back to reference Witkin SS, Gerber S, Ledger WJ (2002) Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin Infect Dis 34:204–209PubMedCrossRef Witkin SS, Gerber S, Ledger WJ (2002) Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin Infect Dis 34:204–209PubMedCrossRef
68.
go back to reference Ouburg S, Bart AC, Klinkenberg-Knol EC, Mulder CJ, Salvador PA, Morre SA (2005) A candidate gene approach of immune mediators effecting the susceptibility to and severity of upper gastrointestinal tract diseases in relation to Helicobacter pylori and Epstein-Barr virus infections. Eur J Gastroenterol Hepatol 17:1213–1224PubMedCrossRef Ouburg S, Bart AC, Klinkenberg-Knol EC, Mulder CJ, Salvador PA, Morre SA (2005) A candidate gene approach of immune mediators effecting the susceptibility to and severity of upper gastrointestinal tract diseases in relation to Helicobacter pylori and Epstein-Barr virus infections. Eur J Gastroenterol Hepatol 17:1213–1224PubMedCrossRef
69.
go back to reference Kim N, Cho SI, Yim JY et al (2006) The effects of genetic polymorphisms of IL-1 and TNF-A on Helicobacter pylori-induced gastroduodenal diseases in Korea. Helicobacter 11:105–112PubMedCrossRef Kim N, Cho SI, Yim JY et al (2006) The effects of genetic polymorphisms of IL-1 and TNF-A on Helicobacter pylori-induced gastroduodenal diseases in Korea. Helicobacter 11:105–112PubMedCrossRef
70.
go back to reference Nieters A, Kallinowski B, Brennan P et al (2006) Hepatitis C and risk of lymphoma: results of the European multicenter case–control study EPILYMPH. Gastroenterology 131:1879–1886PubMedCrossRef Nieters A, Kallinowski B, Brennan P et al (2006) Hepatitis C and risk of lymphoma: results of the European multicenter case–control study EPILYMPH. Gastroenterology 131:1879–1886PubMedCrossRef
71.
go back to reference Rollinson S, Levene AP, Mensah FK et al (2003) Gastric marginal zone lymphoma is associated with polymorphisms in genes involved in inflammatory response and antioxidative capacity. Blood 102:1007–1011PubMedCrossRef Rollinson S, Levene AP, Mensah FK et al (2003) Gastric marginal zone lymphoma is associated with polymorphisms in genes involved in inflammatory response and antioxidative capacity. Blood 102:1007–1011PubMedCrossRef
72.
go back to reference Wu MS, Shun CT, Huang SP, Cheng AL, Chen LT, Lin JT (2004) Effect of interleukin-1beta and glutathione S-transferase genotypes on the development of gastric mucosa-associated lymphoid tissue lymphoma. Haematologica 89:1015–1017PubMed Wu MS, Shun CT, Huang SP, Cheng AL, Chen LT, Lin JT (2004) Effect of interleukin-1beta and glutathione S-transferase genotypes on the development of gastric mucosa-associated lymphoid tissue lymphoma. Haematologica 89:1015–1017PubMed
73.
go back to reference Rothman N, Skibola CF, Wang SS et al (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 7:27–38PubMedCrossRef Rothman N, Skibola CF, Wang SS et al (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 7:27–38PubMedCrossRef
74.
go back to reference Chang ET, Smedby KE, Hjalgrim H et al (2005) Medication use and risk of non-Hodgkin’s lymphoma. Am J Epidemiol 162:965–974PubMedCrossRef Chang ET, Smedby KE, Hjalgrim H et al (2005) Medication use and risk of non-Hodgkin’s lymphoma. Am J Epidemiol 162:965–974PubMedCrossRef
75.
go back to reference Baker JA, Weiss JR, Czuczman MS, Menezes RJ, Ambrosone CB, Moysich KB (2005) Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphoma. Cancer Causes Control 16:301–308PubMedCrossRef Baker JA, Weiss JR, Czuczman MS, Menezes RJ, Ambrosone CB, Moysich KB (2005) Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphoma. Cancer Causes Control 16:301–308PubMedCrossRef
76.
go back to reference Franconi F, Brunelleschi S, Steardo L, Cuomo V (2007) Gender differences in drug responses. Pharmacol Res 55:81–95PubMedCrossRef Franconi F, Brunelleschi S, Steardo L, Cuomo V (2007) Gender differences in drug responses. Pharmacol Res 55:81–95PubMedCrossRef
77.
go back to reference Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749–59PubMedCrossRef Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749–59PubMedCrossRef
78.
go back to reference Jost PJ, Ruland J (2006) Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences and therapeutic implications. Blood 109(7):2700–2707 Jost PJ, Ruland J (2006) Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences and therapeutic implications. Blood 109(7):2700–2707
79.
go back to reference Kato I, Koenig KL, Baptiste MS et al (2003) History of antibiotic use and risk of non-Hodgkin’s lymphoma (NHL). Int J Cancer 107:99–105PubMedCrossRef Kato I, Koenig KL, Baptiste MS et al (2003) History of antibiotic use and risk of non-Hodgkin’s lymphoma (NHL). Int J Cancer 107:99–105PubMedCrossRef
80.
go back to reference Doody MM, Linet MS, Glass AG et al (1996) Risks of non-Hodgkin’s lymphoma, multiple myeloma, and leukemia associated with common medications. Epidemiology 7:131–139PubMedCrossRef Doody MM, Linet MS, Glass AG et al (1996) Risks of non-Hodgkin’s lymphoma, multiple myeloma, and leukemia associated with common medications. Epidemiology 7:131–139PubMedCrossRef
81.
go back to reference Beiderbeck AB, Holly EA, Sturkenboom MC, Coebergh JW, Stricker BH, Leufkens HG (2003) Prescription medications associated with a decreased risk of non-Hodgkin’s lymphoma. Am J Epidemiol 157:510–516PubMedCrossRef Beiderbeck AB, Holly EA, Sturkenboom MC, Coebergh JW, Stricker BH, Leufkens HG (2003) Prescription medications associated with a decreased risk of non-Hodgkin’s lymphoma. Am J Epidemiol 157:510–516PubMedCrossRef
82.
go back to reference Cerhan JR, Wallace RB, Folsom AR et al (1997) Medical history risk factors for non-Hodgkin’s lymphoma in older women. J Natl Cancer Inst 89:314–318PubMed Cerhan JR, Wallace RB, Folsom AR et al (1997) Medical history risk factors for non-Hodgkin’s lymphoma in older women. J Natl Cancer Inst 89:314–318PubMed
Metadata
Title
Joint effect between regular use of non-steroidal anti-inflammatory drugs, variants in inflammatory genes and risk of lymphoma
Authors
Birgit Hoeft
Nikolaus Becker
Evelin Deeg
Lars Beckmann
Alexandra Nieters
Publication date
01-03-2008
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 2/2008
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-007-9082-9

Other articles of this Issue 2/2008

Cancer Causes & Control 2/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine